Erick Gamelin

Part-time Chief Medical Officer

Erick has been a consultant to Step Pharma since Feb 2020 acting as Chief Medical Officer. He brings over thirty years of experience in clinical development and translational cancer research in haematological malignancies. Most recently Erick served as VP and Acting CMO of Oncology for Dynavax. Prior to this he held oncology clinical development executive roles with Macrogenix, Pfizer and earlier Amgen. Prior to joining industry, Erick was professor of Medical Oncology, he was appointed by the French Minister of Health as the CEO of the 500-member Paul Papin University Cancer Centre in France (2005-2009); throughout his career Erick has led over 100 phase I, II, and III clinical trials. He has published over 130 scientific articles in peer-reviewed journals

Erick has successfully participated in the filing for several cancer drugs, such as denosumab, romiplostim.

He is responsible for the clinical development strategy, providing pre-IND and study design clinical leadership to ensure successful transition of STP938 into clinical development.

Erick graduated from Paris University, obtained a Ph.D. from Bordeaux University and did his MD residency at Angers University, France. He did his post-doc at the NIH,  Molecular Therapeutics Section in the Developmental Therapeutics Branch. Erick has been a US resident since 2011 and is based in Los Angeles, California.

Share this page